Prespecified interim analysis of a phase 3 RCT in biopsy-proven IgA nephropathy: povetacicept 80 mg every 4 weeks reduced 24-h urine protein-to-creatinine ratio by 52.0% vs 4.3% with placebo at week 36 (first 199 of 557). Adverse events were similar (75% vs 78%).
RCTn = 557
Barratt et al. Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy